Uchino Hiroshi, Fujishima Junko, Fukuoka Kaori, Iwakiri Teppei, Kamikuri Akira, Maeda Hidenori, Nakama Kazuhiro
Shin Nippon Biomedical Laboratories, Ltd., Drug Safety Research Laboratories.
SNBL USA, Ltd., USA.
J Toxicol Sci. 2017;42(5):629-640. doi: 10.2131/jts.42.629.
The objective of this study was to investigate the availability of novel urinary biomarkers (BMs) such as total protein, albumin, β-microglobulin, clusterin, cystatin C, neutrophil gelatinase-associated lipocalin (NGAL) for the detection of acute nephrotoxicity in cynomolgus monkeys. Animals (total 9 males/3 groups) were administered gentamicin (GM) subcutaneously at 40 mg/kg for 7 days, cisplatin (CDDP) intravenously at 3 mg/kg once and puromycin aminonucleoside (PAN) intravenously at 20 mg/kg for 7 days. Two-hr urine on Days 0, 3, and 6, and 16-hr urine and blood on Days 1, 4, and 7 were collected. Novel urinary BMs and conventional clinical pathology parameters were evaluated in parallel to histopathological and electron microscopic examinations on the kidneys at termination. Urinary BMs and enzymes increased earlier than serum creatinine and blood urea nitrogen, particularly in 2-hr urine after dosing on Day 0, urinary albumin was increased in all groups and urinary NGAL with the highest magnitude of change rate among urinary BMs was observed in the GM and CDDP groups. Degeneration/necrosis and hyaline droplet of renal tubule, cellular cast and dilatation of renal tubule, and hypertrophy of podocytes were observed in the GEN, CDDP, and PAN groups, respectively. These results showed that the increases of urinary BMs reflected the agent-specific renal damages and these urinary BMs could be useful for the detection of segment-specific nephrotoxicity. Urinary albumin and NGAL are the most useful BMs to estimate glomerular and distal tubular damages, respectively, as well as proximal tubular damage in cynomolgus monkeys.
本研究的目的是调查新型尿液生物标志物(BMs),如总蛋白、白蛋白、β-微球蛋白、簇集素、胱抑素C、中性粒细胞明胶酶相关脂质运载蛋白(NGAL)在食蟹猴急性肾毒性检测中的可用性。将动物(共9只雄性/3组)分别皮下注射40mg/kg庆大霉素(GM),连续7天;静脉注射3mg/kg顺铂(CDDP)1次;静脉注射20mg/kg嘌呤霉素氨基核苷(PAN),连续7天。在第0、3和6天收集2小时尿液,在第1、4和7天收集16小时尿液和血液。在实验结束时,将新型尿液BMs和传统临床病理参数与肾脏的组织病理学和电子显微镜检查并行评估。尿液BMs和酶的升高早于血清肌酐和血尿素氮,尤其是在第0天给药后的2小时尿液中,所有组的尿白蛋白均升高,并且在GM组和CDDP组中观察到尿液NGAL在尿液BMs中变化率最高。在GEN组、CDDP组和PAN组中分别观察到肾小管的变性/坏死和透明滴、细胞管型和肾小管扩张以及足细胞肥大。这些结果表明,尿液BMs的升高反映了药物特异性肾损伤,并且这些尿液BMs可用于检测节段特异性肾毒性。尿白蛋白和NGAL分别是评估食蟹猴肾小球和远端肾小管损伤以及近端肾小管损伤最有用的BMs。